Intellia To Take On Pfizer Blockbuster With Gene-Editing Therapy

Aims To Challenge Vyndaqel

 
• By Andrew McConaghie
  
Intellia HQ
It is still early days for its vivo gene-editing therapy NTLA-2001, but Intellia is accelerating its challenge Pfizer. • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip